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Summary
The third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are 
frequently targeted by neutralizing antibodies (nAbs) in infected individuals. In chronic infection, 
HIV-1 escape mutants repopulate the plasma, and V3 and CD4bs nAbs emerge that can neutralize 
heterologous tier 1 easy-to-neutralize, but not tier 2 difficult-to-neutralize HIV-1 isolates. 
However, neutralization sensitivity of autologous plasma viruses to this type of nAb response has 
not been studied. We describe the development and evolution in vivo of antibodies distinguished 
by their target specificity for V3and CD4bs epitopes on autologous tier 2 viruses but not on 
heterologous tier 2 viruses. A surprisingly high fraction of autologous circulating viruses was 
sensitive to these antibodies. These findings demonstrate a role for V3 and CD4bs antibodies in 
constraining the native envelope trimer in vivo to a neutralization-resistant phenotype, explaining 
why HIV-1 transmission generally occurs by tier 2 neutralization-resistant viruses.
Introduction
Inducing antibodies with neutralization breadth is a primary goal of HIV-1 vaccine 
development (Mascola and Haynes, 2013). Broadly neutralizing antibodies (bnAbs) can 
block infection in macaques; however, current HIV-1 envelope (Env) immunogens induce 
only nAbs that inhibit easy-to-neutralize (tier 1) HIV-1 strains. In contrast, bnAbs that 
potently neutralize difficult-to-neutralize (tier 2) HIV-1 strains associated with HIV-1 
transmission are not induced by current vaccines (Mascola and Haynes, 2013).
Initial autologous nAbs in HIV-1-infected subjects are restricted to neutralizing the infecting 
transmitted/founder (T/F) virus (Derdeyn et al., 2014). Epitopes frequently targeted by these 
nAbs are the third constant region-variable loop 4 (C3-V4) domain, the base of the third 
variable (V3) loop, the first and second variable loop (V1V2) regions, and the CD4 binding 
site (CD4bs). In chronic HIV-1 infection, virus escape mutants repopulate the plasma virus 
pool, and neutralization breadth accrues to varying degrees in different persons (Hraber et 
al., 2014). V3 and CD4bs nAbs arise that can neutralize heterologous tier 1 but not tier 2 
HIV-1 isolates (Montefiori et al., 2012; Moore et al., 1994), although heterologous tier 2 
neutralization is seen with some CD4bs (Scheid et al., 2011) and V3 (Gorny et al., 2009; 
Hioe et al., 2010) antibodies. However, neutralization sensitivity of autologous plasma 
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viruses to this type of V3 and CD4bs nAb response has not been studied. Here, we isolated 
from two chronically HIV-1-infected persons V3 and CD4bs neutralizing monoclonal 
antibodies (mAbs) with breadth for tier 1 but not tier 2 heterologous viruses and tested their 
ability to neutralize a large panel of autologous viruses. We also isolated CD4bs bnAbs with 
tier 2 breadth and tested their ability to neutralize the same panel of autologous viruses that 
includes escape mutants. Surprisingly, we found a group of V3 and CD4bs tier 1 
heterologous virus-nAbs that neutralized a proportion of autologous tier 2 viruses. These 
nAbs differ from more common tier 1 virus-reactive antibodies that neutralize autologous 
and heterologous tier 1 viruses exclusively. We suggest that the autologous tier 2-reactive 
V3 and CD4bs nAbs described here play a previously underappreciated role in neutralizing 
autologous tier 1 and tier 2 primary viruses, thus continuously selecting autologous viruses 
for neutralization-resistance. This additional level of immune surveillance against HIV-1 
Env trimers with relaxed or “open” conformations likely contributes to the finding that T/F 
viruses exhibit tier 2 (or greater) neutralization resistance, a finding relevant to HIV-1 
vaccine research.
Results
Restricted or broad nAbs from chronically infected persons
We isolated two B cell clonal lineages (CH13, CH27) and single mAbs from chronically 
clade C HIV-1 infected African person CH0457 known to have plasma broad neutralizing 
activity (Tomaras et al., 2011), using antigen-specific memory B cell sorting of peripheral 
blood mononuclear cells (PBMC) (Fig. 1AB; Table S1). Epitope mapping with virus 
mutants showed CH13 lineage mAbs bound to the CD4bs (Fig. 1C; Tables S2–S3); lineage 
members neutralized 8/8 tier 1,but 0/40 tier 2 heterologous HIV-1 Env pseudoviruses (Fig. 
2). Two other mAbs, CH14 and CH48, were not clonally related and both mapped to the 
HIV-1 Env V3 loop (Fig. 1D; Table S4). Like CD4bs clonal lineage CH13, V3 mAbs CH14 
and CH48 neutralized tier 1 but not tier 2 heterologous HIV-1 strains (Fig. 2).
The second mAb clonal lineage, termed CH27 (Fig. 1B), had 1 IgG1 (CH44) and 2 IgA2 
(CH27, CH28) members (Table S1). All lineage members (CH27, CH28, CH44) neutralized 
40% (range 25–48%) of 40 tier 2 heterologous HIV-1 strains (Fig. 2) and preferentially 
neutralized tier 2 but not tier 1 heterologous viruses. HJ16 is a CD4bs bnAb isolated from 
another infected person and like the CH27 lineage mAbs, HJ16 neutralizes multiple tier 2 
but not tier 1 viruses. Mutation of Env at N276 conferred resistance to HJ16 (Balla-
Jhagjhoorsingh et al., 2013) and CH27 lineage mAbs were sensitive to mutations at N276 
and T278 (Table S3). CH27, CH44 and HJ16 cross-blocked each other for Env binding (Fig. 
S1), showing that CH27 lineage bnAbs were similar to HJ16 (Fig. 2). Serum from 
chronically-infected person CH0457 taken at weeks (wks) 8 and 96 of study were tested 
against the same panel of heterologous viruses (Fig. 2). Neutralization titers and breadth 
were similar at the two chronic infection time points (R2=0.95, Pearson’s correlation 
p<2.2×10−16). The neutralization pattern of CH27 lineage bnAbs accounted for part of 
serum breadth, but some viruses in the panel were neutralized by serum and not the isolated 
mAbs (eg, C.Ce2010_F5 in Fig. 2) indicating that the isolated mAbs only partially 
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recapitulated serum neutralization and that other bnAbs might have been present in this 
person.
From a second person, CH505, previously described to have a CD4bs bnAb lineage 
(represented by CH103 in Fig. 3) (Liao et al., 2013), we isolated by limiting dilution 
memory B cell culture two V3 nAbs (DH151, DH228; Table S4) from 176 and 41 wks after 
transmission, respectively (Fig. 3). DH151 and DH228 neutralization was similarly 
restricted to a subset of tier 1 heterologous viruses and they neutralized 0/16 tier 2 
heterologous viruses (Fig. 3).
Virus evolution in chronically infected person CH0457
We amplified 209 CH0457 env gene sequences by single genome amplification (SGA) from 
10 time points over two years during chronic infection (wks of chronic infection study 0, 2, 
4, 8, 12, 16, 24, 48, 72, 96 post-enrollment). A mean of 21 (range 12–35) SGA env 
sequences were analyzed for each time point. Phylogenetic analysis showed that Env 
sequences continuously evolved over time; Envs from wks 48, 72 and 96 were more 
divergent versus earlier Envs (wk 0–16) (Fig. S2). Furthermore, within-subject phylogeny 
maintained a persistent minority clade that represented a small fraction (mean 14%) of Envs 
sampled at any given time point (Fig, 4; Fig. S2) throughout the study. Consensus of this 
clade differed at 85/888 (9.6%) aligned Env amino acid positions from the main clade 
consensus. Analysis of sequences from CH0457 relative to the database indicated that 
despite the genetic distance, sequences from this minor persistant clade were more closely 
related to other sequences from CH0457 than to heterologous strains (not shown); we further 
validated the relationship of the two clades by identifying transition states between the two 
clades in archival DNA proviral sequences (Fig. S2). The minor clade contained members 
from many sampling time points across two years of infection; a Slatkin-Madison test 
strongly supported compartmentalization (p=0.0001). Interestingly, these two divergent 
virus populations persisted during the 96 wks of sampling without apparent recombination 
between the two clades, although some recombination within the lineages was evident.
Neutralization of autologous viruses by bnAbs and tier 1 virus-nAbs
We made 84 pseudoviruses from these env sequences (Fig. 4B; mean 8 per time point; range 
7–11) to assay against CH0457 serum (Fig. 4A). Later serum time points (wk 72–96) 
potently neutralized early viruses (wk 0–48) but not later viruses, indicating that autologous 
nAbs were continuously elicited during chronic infection in CH0457 (Fig. 4AB).
Assay of CH27 CD4bs lineage bnAbs against these 84 autologous pseudoviruses showed 
that 5 were weakly neutralized by 1/3 lineage CH27 bnAbs (range 32–50 µg/mL), while 79 
(94%) resisted CH27 lineage bnAbs (Fig. 4A; Fig. S3A). This suggested that the autologous 
virus pool in CH0457 had already escaped from pressure exerted by the CH27 lineage 
bnAbs, with viral escape occurring during chronic infection prior to study enrollment.
To seek definitive evidence of selection by CH27 lineage bnAbs, we amplified proviral env 
genes archived in PBMC from the earliest time point (wk 0) in this study. Like plasma-
derived Env pseudoviruses, most PBMC-derived Env pseudoviruses resisted lineage CH27 
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bnAbs (Fig. 4AB). However, two cell-derived Env pseudoviruses (w0.35c, w0.29c) were 
highly sensitive to CH27 lineage bnAbs, thus documenting CH27 bnAb lineage-mediated 
escape (Fig. 4A; Fig. S3B). Remarkably, both sensitive viruses were members of the 
persistent minority clade (Fig. 4B; Fig. S2).
We tested CH0457 tier 1 virus-nAbs (5 CH13 lineage CD4bs mAbs, 2 V3 mAbs CH14, 
CH48) against autologous HIV-1 pseudoviruses and found that the V3 and CD4bs mAbs 
neutralized autologous viruses throughout the 2-year study period, including PBMC-
archived viruses (Fig. 4AB; Fig. S3AB). Remarkably, the CD4bs lineage CH13 tier 1-nAbs 
neutralized 52/84 (62%) and 11/34 (32%) of autologous plasma and PBMC viruses, 
respectively, while V3 tier 1 virus-nAbs (CH14, CH48) neutralized 67/84 (80%) plasma and 
28/34 (82%) PBMC viruses. Tier 1 virus-nAb potency ranged from 0.06–50 µg/mL, with 
potency of ≤2 µg/mL for 21/257 (8%) autologous virus neutralization assays. Sensitivity to 
CH13 lineage and V3 mAbs peaked at wk 24 after enrollment; by wk 48 most viruses 
resisted the V3 mAbs (Fig. 4A; Fig. S3A) suggesting escape from these nAbs. Across all 
time points, 32/84 (38%) autologous pseudoviruses resisted the CD4bs nAbs while 17/84 
(20%) resisted the V3 mAbs. CH0457 Env sequences did not show accumulation of Env 
mutations at nAb contact sites suggested by epitope mapping (Tables S2–S4). Other studies 
have shown that V3 in chronic infection either did not change (Nyambi et al., 2008) or 
accumulated sensitivity mutations over time (Haldar et al., 2011), and V3 epitopes otherwise 
sensitive to mAbs can be occluded by other regions of Env (Upadhyay et al., 2014). Thus, 
both common CD4bs and V3 tier 1 virus-nAbs can select virus escape mutants that shape 
the autologous virus reservoir towards neutralization resistance.
Among viruses sampled between wks 48–96, only 3 were moderately sensitive to the tier 1-
virus nAb CD4bs CH13 lineage (w48.20, w72.2, w72.18), with the rest weakly sensitive or 
completely resistant. These CH0457 viruses were all within the persistent minor clade (3/10 
in minor clade vs. 0/17 in dominant clade; Fisher’s exact test p=0.04). That for both CD4bs 
lineages the sensitive viruses persisted longest in the minor but not the dominant virus clade 
raises the possibility that viruses in the minor clade may be emerging from an 
immunologically protected site (eg, brain or CD4 T cell latent pool) where antibody pressure 
would be limited.
To determine if autologous virus neutralization by autologous tier-1 virus nAbs was unique 
to CH0457, we studied two V3 tier 1 virus-nAbs (DH151, DH228; Table S4) isolated from a 
second HIV-1-infected African person, CH505, 176 and 41 wks after transmission, 
respectively; CH505 also developed a CD4bs clonal lineage (termed CH103) at 136 wks 
after transmission (Liao et al., 2013). CH505 was studied earlier during infection versus 
CH0457, thus Env selection by bnAbs was still ongoing and many autologous Env 
pseudoviruses were only partially resistant to the CH103 bnAb lineage (Fig. S3C) (Gao et 
al., 2014). Both CH505 V3 mAbs (CH151, CH228) neutralized some heterologous tier 1 
viruses but 0/16 tier 2 viruses (Fig. 3). However, V3 mAbs DH151 and DH228 neutralized 
45/96 (47%, IC50 range 0.03–50 µg/mL) autologous CH505 viruses (Fig. 4C; Fig. S3C) and 
potently neutralized 7/96 (7.3 %) viruses at ≤2 µg/mL. Interestingly, the T/F virus from 
CH505 resisted both V3 nAbs but became sensitive by wk 14 (Fig. 4CD; Fig. S3C) showing 
some CH505 autologous viruses had Env V3 epitope exposure by wk 14 after infection. As 
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in CH0457, we did not find Env mutations accumulating at binding sites of these mAbs but 
we did find autologous CH505 viruses sensitive to V3 mAbs at all time points studied. Thus, 
CH505 V3 mAbs DH151 and DH228 had no neutralizing activity against heterologous tier 2 
viruses but neutralized autologous CH505 viruses, indicating that this phenomenon was not 
limited to the chronically HIV-1-infected person CH0457.
Autologous virus neutralization sensitivity
To assess autologous virus susceptibility to heterologous nAbs, we assayed CH0457 
pseudoviruses and found 73/84 (87%) sensitive to heterologous VRC01-like CD4bs bnAb 
CH31 (Wu et al., 2011) and 55/62 (89%) sensitive to loop binding CD4bs bnAb CH106 
(Liao et al., 2013) (Fig. S3A). Glycan-dependent bnAb HJ16 neutralized only 5/72 (7%) 
viruses, consistent with escape from the HJ16-like lineage CH27 nAbs (Fig. S1, Table S3).
To assess overall neutralization sensitivity, we tested 84 CH0457 Env pseudoviruses against 
pooled serum (HIVIG-C) and a subset against well-characterized HIV-1 patient sera 
(Seaman et al., 2010) (Fig. S3D). The data suggested that CH0457 viruses sensitive to 
autologous tier 1 virus-nAbs (CH13 lineage, CH14, CH48) had exposed V3 and CD4bs 
epitopes. We analyzed a subset of Env pseudoviruses (10 sensitive / 10 resistant to 
autologous V3 and CD4bs tier 1 virusnAbs) against heterologous V3 and CD4bs mAbs 
known to not neutralize tier 2 viruses (Gorny et al., 2009; Montefiori et al., 2012) (Fig. 
S4A). Viruses sensitive to autologous tier 1 virus-nAbs were neutralized by heterologous V3 
and CD4bs nAbs, suggesting that V3 loop and CD4bs epitopes were trimer-surface exposed. 
Viruses resistant to autologous nAbs also resisted heterologous nAbs (Fig. S4A). Sensitive 
viruses also had intermediate sensitivity to a panel of neutralization typing sera (Fig. S4A) 
consistent with an intermediate (tier 1B) (Seaman et al., 2010) phenotype (Fig. S4B). 
Autologous viruses from CH505 tested with a similar panel also showed predominant tier 
1B neutralization sensitivity (Fig. S4C). These data showed that viruses from chronic 
infection in African persons CH0457 and CH505 could be neutralized by common V3 and 
CD4bs tier 1 virus-nAbs that lacked tier 2 heterologous virus-neutralizing activity.
Discussion
This study shows that a subset of common CD4bs and V3 antibodies that neutralize tier 1 
but not tier 2 heterologous viruses have the capacity to neutralize autologous tier 2 viruses 
and select for virus escape mutants. This observation is critical to understanding how 
neutralization-resistant T/F viruses are selected and how antibodies with tier 1 virus 
neutralization are induced.
The initial autologous nAb response in acute HIV-1 infection is specific for autologous virus 
with little or no tier 1 heterologous breadth (Richman et al., 2003; Wei et al., 2003). In 
chronic infection breadth develops for heterologous tier 1 viruses and viruses can evolve in 
response to those nAbs (Haldar et al., 2011; Kelly et al., 2005; Nyambi et al., 2008). 
However, autologous virus-neutralizing mAbs isolated from HIV-1-infected people have 
been strictly strain-specific with no detectable heterologous tier 1 or tier 2 HIV-1 
neutralization (Derdeyn et al., 2014) (DC Montefiori, personal communication). This study 
to examines the dynamics of this evolution by combining virus SGA with mAb isolation to 
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deconvolute the polyclonal antibody response in chronically infected persons and 
demonstrate autologous nAbs with both heterologous tier 1 and autologous tier 2 
neutralizing activity. We did not isolate all bnAbs or tier 1 nAbs from these persons. 
However, we have shown ongoing and repeated emergence of viruses sensitive to common 
CD4bs and V3 nAbs. In particular, this class of nAbs does not appear to exert immune 
pressure to the same degree as bnAbs where we found evidence of complete viral escape. It 
is possible that when autologous nAbs begin to show heterologous tier 1 breath they may be 
developing into bnAbs as occurred in the CH103 CD4bs lineage (Liao et al., 2013), but at 
this time it is not known which antibody lineages will mature to breadth.
We found autologous virus isolates were variably neutralized by mAbs against the CD4bs 
and V3 loop (Fig. S4AC). Recent work has shown that sensitive Envs spend more time in 
conformationally open states that permit binding of antibodies without neutralization 
breadth (Munro et al., 2014). Our data show that these sensitive viruses arise during chronic 
HIV-1 infection and are likely the antigenic stimulus inducing common antibodies that 
neutralize tier 1 heterologous viruses. When we tested common CD4bs and V3 nAbs 
isolated from the same subjects against their autologous viruses, the mAbs neutralized both 
the sensitive viruses and a subset of autologous isolates resistant to heterologous tier 1 virus-
nAbs. We speculate that neutralization of resistant viruses was possible because the mAbs 
and viruses co-evolved in the same HIV-1-infected persons and the antibodies gained the 
ability to bind autologous viruses. During HIV-1 infection, virus quasispecies evolve that 
have different degrees of Env reactivity, including viruses with high intrinsic reactivity (tier 
1A) (Seaman et al., 2010) that are more reactive with soluble CD4 and nAbs (Haim et al., 
2011). Our study indicates that autologous viruses with low Env reactivity (tier 1B or tier 2) 
(Haim et al., 2011; 2013) can act as templates for antibody evolution, promoting 
development of nAbs that bind and neutralize autologous virus Envs with low reactivity. 
Such nAbs could broadly react with high reactivity heterologous tier 1A Envs but would be 
expected to bind poorly to low reactivity heterologous tier 2 Envs.
Autologous nAbs that arise in acute HIV-1 infection can exert immune pressure and 
influence T/F virus evolution; the initial autologous-specific nAb response appears within 
the first year of infection and is associated with development of resistant viruses in virtually 
all infected people (Richman et al., 2003; Wei et al., 2003). In addition, tier-1 virus nAbs of 
the type studied here were shown to exert immune pressure in a humanized mouse HIV-1 
infection model (Klein et al., 2014). Our study is unique in showing autologous tier 1 virus-
nAb evolution over time and the ability of those nAbs to combine with tier 2-virus-nAbs to 
shape the neutralization sensistivity of the autologous virus pool.
HIV-1 vaccine efficacy trials have not convincingly shown a protective effect of vaccine-
elicited tier 1 virus-nAbs, although in secondary analyses, tier 1 nAbs correlated with 
decreased risk of infection in VAX004 (Gilbert et al., 2005) and RV144 (Haynes et al., 
2012). The only vaccine study to date that demonstrated any protection (RV144) did not 
elicit tier 2 nAbs (Montefiori et al., 2012). Secondary analyses of RV144 found that V2-
specific antibodies correlated with decreased transmission risk (Gottardo et al., 2013; Zolla-
Pazner et al., 2014); as did antibody dependent cellular cytotoxicity-mediating antibodies 
(Haynes et al., 2012) and V3 antibodies (Gottardo et al., 2013) in the context of other 
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responses such as low Env-IgA (Haynes et al., 2012). Recent studies of HIV-1 Env 
evolution over the pandemic indicate that T/F viruses are evolving to be more resistant to 
bnAbs (Bouvin-Pley et al., 2014); thus a successful vaccine may have to contend with an 
ever increasing degree of resistance among HIV-1 strains. However, we found that some tier 
1 virus-nAbs can neutralize autologous tier 1B and tier 2 HIV-1 Envs with which they co-
evolved (Fig. 4; Fig. S3AC). If a vaccine elicited a sufficiently large and diverse pool of tier 
1 virus-nAbs, some degree of protection might be possible.
Antibodies and autologous viruses are passed together in bodily fluids associated with 
HIV-1 transmission. The present study suggests that viruses with a more sensitive phenotype 
would be passed along with nAbs against those viruses, while resistant viruses would be 
passed without nAbs against them. This situation could cause a selection bias to favor 
infection by viruses resistant to the autologous nAb response. Thus, the observation that T/F 
viruses isolated from recently-infected people are of a more resistant phenotype could be 
partly explained by the restricted tier 1 autologous virus-nAbs described here.
In addition, there is a setting where these kinds of nAbs could be transferred to a susceptible 
host prior to virus exposure—mother-to-child transmission (MTCT). Maternal IgG is 
actively transferred to the fetus (Malek et al., 1996) and maternally-derived nAbs could 
plausibly prevent newborn infection. Thus, V3- or CD4bs-directed nAbs of the type 
described here could correlate with decreased transmission risk for MTCT. A recent analysis 
has shown that a correlate of MTCT transmission risk is low plasma tier 1 virus-nAbs 
(Permar et al., 2015). Boosting to achieve high levels of V3 and CD4bs autologous nAbs in 
pregnant women might be a way to reduce intrapartum and peripartum HIV-1 transmission 
to infants that occurs despite peripartum treatment with anti-retroviral drugs. Thus, tier1 
virus-nAbs can exert selection pressure on autologous virus variants and determine intrinsic 
Env reactivity and sensitivity to neutralization. Whether these common antibodies can be 
harnessed for protection in the setting of vaccination for MTCT remains to be determined.
Experimental Procedures
Flow cytometry, memory B cell cultures and mAb isolation
The gp120ConC core protein was produced and used in flow cytometry on PBMC from 
CH0457 using a two-color technique as described (Gray et al., 2011). IgG+ memory cells 
from CH505 isolated from PBMC were cultured as described (Gao et al., 2014). In both 
cases, Ig genes were amplified from RNA from isolated cells, expression cassettes made and 
mAbs expressed as described (Gao et al., 2014).
Antibody reactivity by binding antibody multiplex assay (BAMA), enzyme-linked 
immunosorbent assay (ELISA) and peptide microarray
Expressed mAbs were assayed for reactivity to HIV-1 antigens using a standardized custom 
BAMA using Luminex (Tomaras et al., 2011). BAMA was performed with a panel of HIV-1 
antigens (gp140ConC, gp120ConC full length, gp140ConB, gp140ConG, gp140JR.FL); mAbs 
with a blank-bead-subtracted value >2000 units and >1000× mAb IgG in µg/mL were 
evaluated further. Binding was confirmed on purified mAbs.
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ELISA was performed as described (Tomaras et al., 2011); testing was considered positive if 
the optical density at 405 nm was >0.3 units and >4-fold over background. Epitope mapping 
by cross-clade peptide microarray was performed as described (Tomaras et al., 2011).
Amplification of full-length env genes and generation of pseudoviruses
After recovery of viral RNA or proviral DNA, 3′ half genomes from plasma or PBMC were 
amplified by single genome amplication (SGA) as described (Salazar-Gonzalez et al., 2009). 
Sequence contigs from each env SGA were assembled and edited using Sequencher 4.7 
(Gene Codes; Ann Arbor, MI). Pseudoviruses were made by adding the CMV promoter to 
the 5′ end of each SGA-amplified env gene then the pPCR product was cotransfected with 
the env-deficient HIV-1 backbone pSG3Δenv into 293T cells.
Neutralization assay in TZM-bl cells
Neutralizing antibody assays in TZM-bl cells were performed as described (Montefiori et 
al., 2012). For some isolates, amino acid substitutions were introduced by oligonucleotide-
directed PCR mutagenesis. Neutralization of pseudoviruses containing Env mutations was 
compared to wild-type pseudovirus. A ≥15-fold increase in IC50 from wild-type to mutant 
was considered positive.
Statistical analysis
Statistical tests were performed in SAS, version 9.2 (SAS Institute, Cary, NC) or in R, 
version 2.15.2 (R Foundation for Statistical Computing, Vienna, Austria). The statistical test 
is noted when p values are presented.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Clonal lineages derived from CH0457
A: The kite-shaped gate shows a diagonal of gp120ConC core+/+ memory B cells that were 
sorted as single cells. Antigen-specific cell frequency was similar in both samples; wk 8 
shown.
B: IgG1 gp120 V3 mAbs (CH14, CH48) were not related to other isolated mAbs. Lineage 
CH13 had 6 IgG1 mAbs (VH1~69/JH3; VK1~39/JK4); mean heavy chain (HC) mutation 
frequency = 9.8%. Lineage CH27 had 3 mAbs—2 IgA2 (CH27, CH28) and a IgG1 (CH44) 
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(VH3~66/JH2; VK3~20/JK1); mean HC mutation frequency = 15.7%. Trees plotted on the 
same scale.
C: Residues critical for lineage CH13 and lineage CH27 mAb binding (Tables S2–3) 
highlighted in the structure of gp120C.YU2 (CD4 light gray, gp120 light blue, mAb 17b not 
shown). Mapped residues are largely located within the CD4-gp120 contact surface. V1/V2 
not shown because it was absent in the crystal structure.
D. CH14 and CH48 binding to peptides reflective of multiple HIV-1 clades. Both bound V3 
loop peptides (residues 301–325) across multiple clades; no binding found for other 
epitopes.
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Figure 2. Heterologous neutralization by mAbs from CH0457
Neutralization of mAbs against tier 1 and tier 2 viruses from diverse clades shown in colored 
boxes (EC50). Control (HIVIG-C) and CH0457 serum from wks 8 and 96 shown; serum 
shown as reciprocal ED50. Lineage CH13 mAbs and non-lineage mAbs (CH14, CH48) 
potently neutralized tier 1 viruses but only neutralized one tier 2 virus (C.246F_C1G). 
Lineage CH27 neutralized one tier 1 virus but 23/40 (58%) tier 2 viruses. CH0457 serum 
from wks 8 and 96 neutralized all tier 1 viruses at >1:20, and 37/40 (93%) and 31/40 (78%) 
of tier 2 viruses, respectively.
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Figure 3. Heterologous neutralization by mAbs from CH505
V3 mAbs DH151 and DH228 from CH505 tested against heterologous HIV isolates. Tier 1 
isolates (2/4) neutralized; 0/16 tier 2 isolates neutralized.
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Figure 4. Autologous neutralization and Env sequence phylogenies
Neutralization heat map of autologous serum and mAbs shown (AC). Each row in the 
neutralization panel (A) of 84 CH0457 pseudoviruses and phylogeny tree (B) is a distinct 
Env isolate spanning wk 0 (enrollment; red) to wk 96 after enrollment (purple). PBMC 
provirus sequences are grey. Autologous serum neutralization (reciprocal dilution) and 
isolated mAbs (µg/mL) shown for (A) lineage CH13 mAbs (tier 1 CD4bs), lineage CH27 
mAbs (tier 2 CD4bs), and CH14 and CH48 (tier 1 V3); and (C) CH505 mAbs DH151 and 
DH228 (tier 1 V3) and lineage CH103 (tier 2 CD4bs). (D) CH505 Env phylogeny spans 
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transmission (wk 0, red) through wk 100 (purple). A high fraction of circulating viruses 
were sensitive to autologous mAbs.
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